Barinthus Biotherapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, revenue was USD 0.802 million compared to USD 38.25 million a year ago. Net loss was USD 56.05 million compared to net income of USD 26.53 million a year ago. Basic loss per share from continuing operations was USD 1.46 compared to basic earnings per share from continuing operations of USD 0.71 a year ago. Diluted loss per share from continuing operations was USD 1.46 compared to diluted earnings per share from continuing operations of USD 0.69 a year ago.